Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fate Therapeutics
(NQ:
FATE
)
3.800
-0.070 (-1.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fate Therapeutics
< Previous
1
2
3
4
Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm
January 29, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
January 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
January 26, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
January 26, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
January 25, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE
January 25, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)
January 24, 2023
From
Robbins LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 24, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate
January 24, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 24, 2023
From
The Schall Law Firm
Via
Business Wire
FATE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
January 23, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 23, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 23, 2023
From
Kirby McInerney LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors
January 23, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
January 23, 2023
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
January 23, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 23, 2023
From
The Schall Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 19, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
January 18, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 18, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
January 18, 2023
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 17, 2023
From
Law Offices of Frank R. Cruz
Via
Business Wire
FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm
January 11, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 09, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 06, 2023
From
The Schall Law Firm
Via
Business Wire
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
January 05, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.